Dogwood Therapeutics completes business combination with Sealbond; approves equity plan adding 2.78M shares

Dogwood Therapeutics, Inc.

Stockholders approved the potential issuance of common stock upon conversion of Series A, A-1, and A-2 preferred stock.
Business combination with Sealbond Limited (per Share Exchange Agreement dated Oct 7, 2024) is now complete.
Second Amended and Restated Equity Incentive Plan approved, increasing reserved shares from 191,122 to 2,972,787.
Special meeting quorum: 820,239 shares (35.76% of voting power) as of Oct 14, 2025 record date.
All five proposals passed with >772K votes for, including adjournment and plan approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.